Optiscan Imaging Limited Overview
Optiscan Imaging is a Melbourne-based, micro-cap medical technology company that designs and manufactures miniaturised confocal laser endomicroscopes — handheld and probe-based microscopes that image living tissue at single-cell resolution in real time, without physically removing and processing a biopsy. After roughly three decades as a component and OEM supplier (most notably as the imaging engine inside Carl Zeiss Meditec's CONVIVO neurosurgical system and, historically, Pentax's ISC-1000 GI endomicroscope), the company has pivoted under CEO Dr Camile Farah toward its own branded clinical devices: InVue (precision surgery), InForm (digital pathology) and InSpecta (veterinary). FY2026 marked the transition to a clinical-stage device company: InSpecta was launched commercially in the US veterinary market in July 2026, and FDA 510(k) submissions were lodged for InForm (1 October 2026) and InVue (5 October 2026). Revenue remains negligible (A$0.45M in FY2026); value hinges on regulatory clearance and commercial adoption.
Company's own description. The FY2026 Annual Report describes Optiscan as a global leader in developing, manufacturing and commercialising imaging technologies for medical, translational and pre-clinical applications, whose technology enables real-time, non-destructive, three-dimensional, in-vivo digital imaging at the single-cell level and links surgery with pathology. The Directors' Report defines the principal activity as the development, manufacture and commercialisation of proprietary confocal imaging devices and digital solutions for surgical, pathology and veterinary applications, advanced through product development, clinical studies, regulatory activities, strategic collaborations and commercialisation in Australia, the United States and other markets (FY2026 AR, Directors' Report).
What the technology does. Optiscan's core intellectual property is a miniaturised fibre-optic confocal scanning microscope. A probe is placed in direct contact with tissue (typically after a fluorescent contrast agent such as fluorescein is applied), and a laser scans an optical section beneath the tissue surface, generating microscopic images that resemble histology in seconds. The company's marketing materials contrast this with conventional pathology workflows (tissue excision, fixation, sectioning, staining, review), which can take hours to days. The intended clinical value propositions are: (i) intraoperative margin assessment — helping surgeons determine whether cancerous tissue remains at the resection margin, potentially reducing re-operations; (ii) rapid ex vivo digital pathology — imaging fresh excised specimens without frozen-section processing; (iii) telepathology — streaming images to remote pathologists; and (iv) AI-assisted detection of cancerous and precancerous tissue.
Business model and revenue model. Historically Optiscan earned revenue from three sources: (a) OEM supply of imaging components and systems to Carl Zeiss Meditec (CZM) for the ZEISS CONVIVO neurosurgical endomicroscope; (b) sales of its research-grade ViewnVivo (formerly FIVE2) pre-clinical/translational imaging system to research institutions; and (c) services (repairs, out-of-warranty servicing) and system rentals. In FY2026, statutory revenue of A$448,769 comprised A$347,377 of goods sold and A$101,392 of services (FY2026 AR, Note 5). The intended future model is a hardware-plus-consumables-plus-software ("razor/razor-blade plus SaaS") model: capital sales of InVue, InForm and InSpecta systems, recurring sales of sterile disposable sheaths/drapes, and a cloud-based telepathology platform that management describes as a scalable recurring software revenue opportunity (FY2026 AR, pipeline table). Licensing is not currently a material revenue line.
Non-operating income is economically more important than revenue today: FY2026 "other income" of A$3.71M comprised the Australian R&D Tax Incentive (A$2.40M, a refundable 43.5% offset for companies with turnover under A$20M), Cooperative Research Centres Projects (CRC-P) grant income (A$0.77M), and interest income (A$0.55M) (FY2026 AR, Note 6).
Value chain position. Optiscan is vertically integrated across design, engineering, software, manufacturing/assembly (Mulgrave), quality systems and clinical research. It relies on external suppliers (several overseas) for key components (FY2026 AR, risk statement). Historically it sat upstream as an OEM component supplier to large device makers; it is now moving downstream to sell branded systems directly and via distributors. The company notes that the "vast majority" of its sales have been through distribution networks with formal agreements including minimum purchase requirements (FY2026 AR, distribution network risk).
Customer types and end-markets.
Independent characterisation. Optiscan is best understood as a long-duration, pre-commercial platform technology company with a small legacy OEM revenue stream that is now in decline. Its most important asset is a mature, miniaturised confocal hardware platform proven in a regulated OEM product (CONVIVO), giving it manufacturing and quality-system credibility unusual for a company of its size. The strategic pivot since 2021 has been to monetise that platform in its own name across multiple indications simultaneously. The risk profile is binary-leaning: FY2027 outcomes on the two pending 510(k) submissions and early InSpecta sales traction will largely determine whether the company becomes a revenue-generating device business or continues to rely on equity raises and R&D tax refunds.
Strategy
Stated strategy (paraphrased from FY2026 AR Chairman's letter, CEO review and Likely Developments). Management frames FY2026 as the year Optiscan moved from technology developer to clinical-stage medical device company. The strategic pillars are: (1) regulatory execution — FDA submissions for InVue and InForm, building on the InSpecta dossier; (2) clinical evidence generation — multi-site studies in Australia, the US (Mayo Clinic) and Europe; (3) commercial readiness — market segmentation, customer analysis, commercial modelling and sales enablement, with InSpecta as first market entry; (4) strategic partnerships — Mayo Clinic, Australian Clinical Labs, Monash University, Long Grove Pharmaceuticals; and (5) next-generation platform development — robotics, telepathology, AI/ML and flexible GI endomicroscopy.
Strategic initiatives announced in the last 24 months.
Remuneration-linked strategic priorities (FY2026 STI framework): regulatory clearances and submissions; product launch activities; revenue growth; expansion of non-dilutive funding; strategic commercial partnerships; budget/cash management; supply-chain resilience.
ESG/sustainability commitments: None disclosed.
Cost programs: None disclosed; administration costs fell 15% in FY2026 without a formal program.
Medium-term financial targets/guidance: Optiscan provides no quantitative financial guidance (revenue, margin or breakeven targets). Its guidance is milestone-based: next-12-month catalysts identified in the FY2026 AR are pivotal clinical study initiation, FDA submissions (now achieved), manufacturing scale-up readiness and commercial launch preparation.
Products & Services
All products fall within the single confocal microscope segment. Pricing for every product is not publicly disclosed.
InVue™ — precision surgery imaging device (flagship human device)
Description: Handheld, miniaturised confocal endomicroscope for in vivo, intraoperative imaging of tissue at the surgical site, intended to support real-time margin assessment.
Key capabilities: Real-time cellular-level imaging via tissue contact; miniaturised surgical probe (used in RMH breast study); integration pathway with telepathology and AI; robotic accessory development with Mayo Clinic.
Target customer: Surgical oncologists (breast, head & neck, oral & maxillofacial), hospital operating rooms; future robotic surgery programs.
Launch/version: Unveiled June 2024; FDA 510(k) lodged 5 October 2026.
Clinical evidence: RMH breast study (Melbourne; second site at Frances Perry House) — 34 of 50 patients enrolled (68%) as at 30 June 2026; St John of God Murdoch (Perth) head & neck study (stage 2 commenced mid-July 2026); Mayo Clinic US studies (breast; 35-patient head & neck at Mayo Rochester led by Kyle Ettinger, MD).
Pricing model: Not publicly disclosed; expected capital + disposables.
InForm™ — digital pathology imaging device
Description: Benchtop/ex vivo confocal imaging device to image freshly excised tissue specimens in pathology workflows without conventional slide preparation.
Key capabilities: Rapid ex vivo digital imaging; telepathology streaming; dataset generation for AI.
Target customer: Anatomical pathology laboratories, hospital pathology departments, surgical suites requiring rapid specimen assessment.
Clinical evidence: ACL collaboration — 60 datasets generated by June 2026, 84 cases imaged by 10 September 2026; 105 tissue datasets collected across clinical sites as at 30 June 2026 (FY2026 AR).
InSpecta™ — veterinary microscopic imaging device
Description: Veterinary-first version of the imaging platform designed for veterinary practices.
Key capabilities: Point-of-care microscopic tissue imaging for animal patients.
Target customer: US veterinary general practices, specialists and practice groups.
Launch/version: FDA CVM regulatory dossier submitted 31 March 2026; US commercial launch 7 July 2026 at AVMA Convention 2026 (Anaheim). First commercially launched Optiscan-branded clinical device. (Note: veterinary devices do not require FDA premarket clearance in the same manner as human devices; the company characterises the dossier submission as meeting FDA requirements.)
Pricing model: Not publicly disclosed.
InVivage® — intra-oral endomicroscope
Description: Confocal endomicroscope designed for oral cavity imaging to distinguish normal, precancerous and cancerous tissue (oral cancer screening/surgery).
Status: FDA 510(k) submitted September 2022 quarter; FDA advised in March 2023 that the first-in-class nature required a De Novo pathway, with additional studies (including on the fluorescent contrast agent as a combination product). A revised InVivage with improved user interface was unveiled in the December 2023 quarter. Regulatory progress since then has been subordinated to InVue/InForm; current De Novo submission status is not publicly disclosed.
Target customer: Oral medicine specialists, dental/ENT.
ViewnVivo™ (formerly FIVE2) — pre-clinical/translational research system
Description: Miniaturised in vivo confocal imaging system for life sciences, pre-clinical and translational research.
Target customer: University and pharmaceutical research laboratories; historically sold to China-based customers.
Status: Commercial; FY2026 sales declined (cited as a cause of the 53% revenue fall). FY2025 China revenue A$191,142; FY2026 nil.
ZEISS CONVIVO® imaging engine (OEM supply to Carl Zeiss Meditec)
Description: Optiscan's confocal imaging technology is the primary imaging component of the ZEISS CONVIVO, a neurosurgical endomicroscopy system with CE Mark and FDA 510(k) clearance.
Customer: Carl Zeiss Meditec AG (Germany), under a Co-operation Agreement.
Status: Commercial; FY2026 revenue from Germany A$378,174 (FY2025: A$629,400). Orders declined in FY2026.
Pentax ISC-1000 (legacy)
- Historic collaboration delivering a GI flexible endomicroscope. No current revenue disclosed.
Software and platform programs
| Program | Description | Stage (30 Jun 2026) |
|---|---|---|
| Telepathology platform | Cloud-based real-time image streaming between clinicians and pathologists; MVP completed; devices updated for compatibility | Validation in real-world settings; positioned as recurring software revenue |
| AI/ML applications | Automated detection of cancerous/precancerous lesions; Monash University agreement under CRC-P; annotation of oral, breast and GI images | Development |
| Robotics platform | Robotic-enabled confocal imaging platform and probe accessories for robotic instruments, co-developed with Mayo Clinic; robotic-assisted breast procedures as first application | Prototyping → pre-clinical |
| Flexible GI endomicroscope | Edge-AI-enabled flexible endomicroscope; architecture complete; GI images collected at University Medical Center Mainz (Germany) | Development under A$3M CRC-P grant |
Services and consumables
-
Repairs, out-of-warranty servicing, system rentals (FY2026 services revenue A$101,392).
-
Sterile disposable sheath and drape accessories developed for InVivage and other devices (Dec 2023 quarterly) — expected to form a recurring consumables line.
Financial Narrative
Income statement — five-year summary
FY2022 growth calculated against FY2021 sales revenue of ~A$889k (IBISWorld aggregator). Diluted EPS equals basic because options are anti-dilutive in loss years.
Revenue CAGR FY2022–FY2026: -18.4% per annum (A$1.013M → A$0.449M).
Commentary. Revenue peaked in FY2023 at A$1.68M on strong CZM and ViewnVivo orders, then declined for three consecutive years as CZM order volumes fell and research-system sales slowed. Losses widened from A$4.2M (FY2022) to A$7.0M (FY2026) as the company deliberately scaled R&D, clinical and regulatory spending under the multi-device strategy. Per-share losses have been held around -0.7 cents because the share count rose with each equity raise. The FY2026 inflection is strategic rather than financial: the company now has a launched product (InSpecta) and two 510(k)s under review, but no revenue contribution from these yet appears in the accounts.
Income statement — detailed (FY2025–FY2026)
Source: FY2026 AR consolidated statement of profit or loss; Notes 6 and 7. The EBITDA margins computed here (-648.2% and -1585.6%) match the "operating margin" series reported by InvestSmart, confirming consistency.
Commentary. Total expenses rose 7.6% to A$11.13M. R&D and IP expense grew 23.3% (A$5.09M → A$6.28M) as three devices were refined to production-ready standard for multiple clinical studies, while administration costs fell 15.4%. Share-based payments quadrupled following adoption of The Reward Practice's remuneration recommendations (more equity-based pay). Gross margin compressed as volume fell. Interest income rose with the larger post-raise cash balance. Employee benefits expense (ex-superannuation) was A$4.12M (FY2025: A$3.74M) and superannuation A$0.40M.
Balance sheet
Source: FY2026 AR statement of financial position; Appendix 4E. Debt comprises lease liabilities on the Mulgrave head office (renewed May 2025 for eight years) and an unsecured insurance premium funding loan (A$29,699 at 30 June 2026). Goodwill is nil.
Three-year equity and liquidity context.
FY2024 equity from FY2026 AR statement of changes in equity (opening balance 1 July 2024); FY2024 cash (A$6.10M) from FY2025 cash flow statement opening balance plus A$5.14M term deposits drawn down in FY2025.
Commentary. The balance sheet was recapitalised by the September 2025 entitlement offer, lifting net assets by A$11.2M to A$18.9M. Liabilities are modest and almost entirely operating (payables, employee provisions, office lease). Inventory rose 40% to A$2.35M — more than five times FY2026 revenue — reflecting deliberate stockpiling of key components to mitigate supply-chain risk and build devices for clinical studies and InSpecta launch. Receivables are dominated by the accrued FY2026 R&D tax incentive (A$2.40M), which converts to cash in FY2027. Accumulated losses stand at A$88.3M against issued capital of A$106.1M. Unrecognised tax losses total A$64.1M (potential benefit A$16.0M at 25%), subject to continuity-of-ownership or same-business tests.
Cash flow
FY2022–FY2024 from Stockopedia (rounded to A$0.01M); FY2025–FY2026 from FY2026 AR.
FY2026 operating cash flow components (FY2026 AR): receipts from customers A$0.72M; payments to suppliers and employees A$10.90M; interest received A$0.55M; R&D tax incentive received A$1.69M; government grants received A$0.84M.
Commentary. Free cash burn has roughly doubled since FY2023 (A$3.3M → A$7.4M). The company has funded this through two large equity raises (FY2024 ~A$16.7M gross; FY2026 A$17.75M gross), with no debt financing. At the FY2026 burn rate and 30 June 2026 cash of A$14.35M — plus an expected ~A$2.4M R&D tax refund in FY2027 — the implied runway is roughly two years before additional capital, absent revenue growth. The Q3 FY2026 quarterly operating outflow was A$2.42M (Quartr summary of Appendix 4C), indicating burn was running above the annual average late in the year; a further step-up is likely as US studies, two FDA reviews and InSpecta commercialisation run in parallel.
Ratios
ROIC, net debt/EBITDA and interest coverage are not meaningful (negative EBIT/EBITDA and net cash). The cash conversion cycle is not meaningful: inventory of A$2.35M against annual cost of sales of A$0.26M implies inventory days in the thousands, reflecting pre-commercial build rather than trading efficiency. Trade receivables were only A$45k at 30 June 2026, all current.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Confocal microscopes segment revenue (AUD K) | 1,156 | 952 | 449 |
Segment revenue YoY growth (%) | -31.2 | -17.6 | -52.9 |
Share of total revenue (%) | 100 | 100 | 100 |
Revenue by Segment and Revenue by Segment (%)
| Metric | FY2025 | FY2026 |
|---|---|---|
Sale of goods (AUD K) | 877 | 347 |
Services (AUD K) | 75 | 101 |
Goods share of revenue (%) | 92.2 | 77.4 |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (AUD K) | 1,013 | 1,680 | 1,156 | 952 | 449 |
Revenue YoY growth (%) | 13.9 | 65.9 | -31.2 | -17.6 | -52.9 |
Pre-tax loss (AUD K) | -4,233 | -4,352 | -6,060 | -6,292 | -6,973 |
Net loss after tax (AUD K) | -4,233 | -4,352 | -6,060 | -6,312 | -6,986 |
Basic EPS (AUD cents) | -0.68 | -0.70 | -0.74 | -0.76 | -0.70 |
Diluted EPS (AUD cents) | -0.68 | -0.70 | -0.74 | -0.76 | -0.70 |
Dividends per share (AUD cents) | 0 | 0 | 0 | 0 | 0 |
Net margin (%) | -417.9 | -259.0 | -524.4 | -663.1 | -1,556.7 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Margin Analysis (%) (FY2025–FY2026)
| Metric | FY2025 | FY2026 |
|---|---|---|
Revenue (AUD K) | 952 | 449 |
Cost of sales (AUD K) | 472 | 262 |
Gross profit (AUD K) | 480 | 186 |
Gross margin (%) | 50.4 | 41.5 |
Other income — R&D tax incentive (AUD K) | 2,410 | 2,398 |
Other income — CRC-P grant (AUD K) | 362 | 766 |
Other income — interest (AUD K) | 335 | 546 |
R&D and IP expenses (AUD K) | 5,093 | 6,282 |
Share-based payment expense (AUD K) | 157 | 654 |
Depreciation and amortisation (AUD K) | 430 | 323 |
Administration and general expenses (AUD K) | 4,173 | 3,531 |
Finance costs (AUD K) | 26 | 82 |
Operating loss / EBIT (AUD K) | -6,600 | -7,438 |
EBITDA (AUD K) | -6,171 | -7,116 |
Operating margin (%) | -693.3 | -1,657.4 |
EBITDA margin (%) | -648.2 | -1,585.6 |
Income tax expense (AUD K) | 20 | 13 |
Balance Sheet and Per-Share Data
| Metric | FY2025 | FY2026 |
|---|---|---|
Total assets (AUD K) | 10,555 | 22,030 |
Cash and cash equivalents (AUD K) | 4,552 | 14,352 |
Trade and other receivables (AUD K) | 2,130 | 2,846 |
Inventories (AUD K) | 1,674 | 2,348 |
Property, plant and equipment (AUD K) | 247 | 390 |
Intangibles incl. goodwill (AUD K) | 5 | 3 |
Right-of-use assets (AUD K) | 1,440 | 1,256 |
Total liabilities (AUD K) | 2,843 | 3,085 |
Short-term debt incl. current lease liabilities (AUD K) | 166 | 177 |
Long-term debt incl. non-current lease liabilities (AUD K) | 1,315 | 1,167 |
Total debt incl. leases (AUD K) | 1,481 | 1,345 |
Net debt (negative = net cash) (AUD K) | -3,071 | -13,007 |
Total equity (AUD K) | 7,712 | 18,945 |
Working capital (AUD K) | 7,355 | 18,502 |
Net tangible assets per share (AUD cents) | 0.92 | 1.82 |
Balance Sheet
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Total equity (AUD K) | 13,867 | 7,712 | 18,945 |
Cash plus term deposits (AUD K) | 11,242 | 4,552 | 14,352 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (AUD K) | -3,830 | -3,150 | -5,740 | -6,212 | -7,104 |
Capital expenditure (AUD K) | -124 | -127 | -87 | -93 | -256 |
Free cash flow (AUD K) | -3,954 | -3,277 | -5,827 | -6,305 | -7,360 |
Financing cash flow (AUD K) | 45 | -374 | 16,200 | -382 | 17,171 |
Dividends paid (AUD K) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (AUD K) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2025 | FY2026 |
|---|---|---|
Return on equity, year-end basis (%) | -81.8 | -36.9 |
Return on assets, year-end basis (%) | -59.8 | -31.7 |
Current ratio (x) | 5.87 | 10.85 |
Debt to equity incl. leases (x) | 0.19 | 0.07 |
Asset turnover (x) | 0.09 | 0.02 |
Revenue by Region
| Region / Country | FY2025 | FY2026 |
|---|---|---|
Germany revenue (AUD K) | 629 | 378 |
China revenue (AUD K) | 191 | 0 |
Australia revenue (AUD K) | 57 | 0 |
United States revenue (AUD K) | 75 | 71 |
Total revenue (AUD K) | 952 | 449 |
Revenue by Region by Region
| Region | FY2025 | FY2026 |
|---|---|---|
EMEA revenue (AUD K) | 629 | 378 |
APAC revenue (AUD K) | 248 | 0 |
Americas revenue (AUD K) | 75 | 71 |
Revenue by Region (%)
| Region (%) | FY2026 YoY growth (%) | FY2026 share (%) |
|---|---|---|
EMEA (Germany) | -39.9 | 84.3 |
APAC (China, Australia) | -100.0 | 0.0 |
Americas (US) | -5.4 | 15.7 |
Share Price and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Share price at FY end (AUD) | 0.11 | 0.08 | 0.24 | 0.11 | 0.12 |
Share price at FY start (AUD) | 0.23 | 0.11 | 0.08 | 0.24 | 0.11 |
FY share price change (%) | -52.2 | -27.3 | 200.0 | -54.2 | 9.1 |
Market Valuation
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Market capitalisation at FY end (AUD Mn) | 196 | 92 | 125 |
Valuation Multiples
| Multiple | Optiscan | Notes |
|---|---|---|
EV | ~A$138M | Market cap less A$14.35M cash plus A$1.35M debt (cash has since declined with burn) |
EV/Sales (FY2026) | ~308x | On A$0.45M revenue; MarketScreener showed EV/Sales FY2026 of ~31x using a different (total income-based) denominator |
P/B | ~8.0x | On A$18.9M book value |
Price/NTA | ~8.0x | NTA 1.82 cents/share |
Capital Instruments
| Instrument | Number | Terms |
|---|---|---|
Ordinary shares | 1,044,176,632 | At 30 June 2026 |
Options — CEO legacy | 9,000,000 | A$0.1925; expire 9 Mar 2027; VWAP hurdles A$1.00–A$2.00 |
Options — Oct 2023 grant | 200,000 | A$0.081; expire 7 Jun 2027 |
Options — Dec 2025 grants | 8,882,904 | A$0.15; expire 13 Jan 2030 |
Performance rights | 3,135,691 | Nil exercise; milestone/service vesting; expire 13 Jan 2030 |
Analyst Conclusions
Management guidance. No financial guidance is given. Operational guidance in the FY2026 AR focused on: lodging FDA dossiers for InVue and InForm (achieved October 2026); generating clinical evidence in Australia and at Mayo Clinic; building InSpecta market awareness and sales in the US veterinary market; advancing the next-generation flexible endomicroscope and strategic collaborations; and manufacturing scale-up readiness. Management cautions that regulatory and commercial timing remains subject to a range of factors.
Consensus growth expectations. None available (no coverage).
Bull case.
-
Regulatory de-risking is concentrated in the next 12 months. With two 510(k) submissions under review (InForm, InVue) and a third device already on market, clearance of even one human device converts Optiscan from a development story into a US commercial medtech business, likely re-rating the stock.
-
Platform economics. One miniaturised confocal engine underpins surgery, pathology, veterinary, GI and robotic applications; the CONVIVO OEM history and a full-device QMS suggest manufacturing can scale, and disposables plus telepathology could produce recurring revenue.
-
Validation from tier-one partners and committed capital. Mayo Clinic's financial interest and two US studies, ACL's pathology network evaluation, and a fully underwritten A$17.75M raise backed by ~52% anchor holders provide evidence quality and funding stability unusual for an ASX micro-cap.
Bear case.
-
Revenue is collapsing while burn rises. Revenue fell 53% to A$0.45M with 84% from one declining OEM customer, while free cash outflow reached A$7.36M; at this trajectory, a further raise is probable within roughly two years, with dilution risk at current prices.
-
Thin evidence base and regulatory precedent. Only 44 patients had been imaged with InVue/InForm at 30 June 2026; the 2023 InVivage experience shows FDA can deem Optiscan's devices first-in-class and demand De Novo submissions, potentially delaying revenue.
-
Crowded, better-funded competitive field. Perimeter (FDA PMA approval, US$2.3M revenue growing 172%), Lumicell and Invenio are ahead commercially in breast margins and rapid pathology; Mauna Kea's restructuring shows how hard it is to build a profitable optical biopsy business. A ~300x EV/Sales valuation leaves little room for setbacks.
Key catalysts and monitorables (next 12 months).
Analyst verdict.
Optiscan enters FY2027 at the most consequential juncture in its 30-year history. The company has done what it said it would in FY2026: it lodged its first FDA dossier, launched InSpecta commercially in the United States, expanded its clinical footprint to six sites including Mayo Clinic, raised A$17.75M on a fully underwritten basis, and — within the first week of October 2026 — lodged 510(k) submissions for both of its flagship human devices. Execution against stated milestones has been credible, and management deserves recognition for converting a long-dormant OEM technology into a multi-indication, regulator-facing product family.
The financial reality, however, is unforgiving. Statutory revenue of A$0.45M is not merely small but shrinking, overwhelmingly dependent on a single German OEM customer whose orders are falling. Cash burn is rising toward A$7.5M per year, and the A$14.35M June 2026 cash balance, supplemented by tax refunds, provides roughly two years of runway — enough to reach FDA decisions, but probably not enough to build a self-funding US commercial organisation. At ~A$150M market capitalisation, investors are effectively paying for regulatory and adoption optionality rather than existing business value.
The investment case therefore rests on three verifiable questions over the next 12–18 months: whether FDA clears InVue and/or InForm through the 510(k) pathway without redirection to De Novo; whether InSpecta generates measurable unit sales demonstrating that Optiscan can sell, install and support its own devices; and whether the Mayo and ACL relationships progress from research into commercial or OEM arrangements. Positive answers would validate the platform and justify the current premium; adverse outcomes, particularly a repeat of the 2023 InVivage experience, would likely force a dilutive raise at lower prices. On balance, Optiscan is a high-risk, event-driven special situation: technically credible, well-governed for its size and well-supported by anchor shareholders, but with value that remains contingent rather than demonstrated. Position sizing should reflect binary regulatory risk.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Background | Committees | Shares held | Other interests |
|---|---|---|---|---|---|
Robert Cooke | Non-executive Chairman | B.Health Admin, Grad Dip Acc & Fin; 40+ years in healthcare; MD & CEO of Healthscope 2010–2017; MD of Connelly Partners (since 2018); Chair of Genesis Cancer Care and Midas Healthcare. Former director of Memphasys Ltd (Apr 2022–Nov 2024) | Audit & Risk (member) | 362,500 | 419,094 performance rights |
Dr Camile Farah | CEO & Managing Director | BDSc, MDSc (OralMed OralPath), PhD, MBA and multiple fellowships; clinician-scientist in oral medicine/pathology, digital pathology and precision oncology; 25+ years across medtech, life sciences and academia; prior CEO/board roles in diagnostics companies | — | 9,135,279 | 15,157,719 unlisted options; 1,191,962 performance rights |
Karen Borg | Non-executive Director | B.Arts (Sydney); CEO of SomnoMed Ltd (ASX: SOM); former President APAC & Middle East at ResMed; senior roles at Johnson & Johnson Medical Devices; former CEO of Catholic Healthcare, Healthdirect, Jobs for NSW | Remuneration & Nomination (Chair); Audit & Risk (member) | 335,010 | 230,502 performance rights |
Ron Song | Non-executive Director | 25-year business career in Australia; former MD of Premium Automobiles (Audi importer, Singapore); credited with raising capital for Optiscan. Director of SomnoMed Ltd since Nov 2020 | Audit & Risk (Chair); Remuneration & Nomination (member) | 1,250,000 | 230,502 performance rights |
Sean Gardiner | Non-executive Director (Clermont/Orchid nominee) | B.Com (PGDA) Cape Town; MD and Head of Private Investments, Clermont Group; 20 years at Morgan Stanley equity research (Head of ASEAN Research). Former director Energy World Corp (2022–2023) | Audit & Risk; Remuneration & Nomination (member) | Nil personally | 184,401 performance rights held by Orchid Capital Investments |
Executive Leadership Team
| Name | Title | Tenure | Notes |
|---|---|---|---|
Dr Camile Farah | CEO & Managing Director | Since 13 Dec 2021 | Fixed remuneration A$430,930 + super; 6 months' notice (executive), 12 months (company) |
Darius Ooi | Chief Financial Officer | Since 1 Apr 2025 | Fixed remuneration A$178,572 + super; 3 months' notice |
Belinda Williamson | Chief Commercial Officer | 2025– (per GlobalData; not confirmed in annual report) | Not KMP |
Elissa Hansen | Company Secretary | — | Chartered Secretary, 20+ years' governance experience |
“—” = not publicly disclosed.
Directors' Remuneration
| Name | Cash salary/fees | STI | Annual leave | Super | LSL | Share-based | Total |
|---|---|---|---|---|---|---|---|
Robert Cooke | 90,909 | 0 | 0 | 10,909 | 0 | 48,196 | 150,014 |
Ron Song | 50,000 | 0 | 0 | 6,000 | 0 | 26,508 | 82,508 |
Karen Borg | 50,000 | 0 | 0 | 6,000 | 0 | 26,508 | 82,508 |
Sean Gardiner | 0 | 0 | 0 | 0 | 0 | 21,206 | 21,206 |
Camile Farah | 452,642 | 81,084 | 29,976 | 30,000 | 6,616 | 317,510 | 917,828 |
Darius Ooi | 178,572 | 23,100 | 10,347 | 24,200 | 1,933 | 36,796 | 274,948 |
Total | 822,123 | 104,184 | 40,323 | 77,109 | 8,549 | 476,724 | 1,529,012 |
Directors' Remuneration (Annual)
| Metric | FY2025 | FY2026 |
|---|---|---|
CEO total remuneration (AUD K) | 823 | 918 |
CEO STI payout (AUD K) | 191 | 81 |
CEO share-based payments (AUD K) | 143 | 318 |
Major Shareholders
| Rank | Holder | Shares | % |
|---|---|---|---|
| 1 | Peters Investments Pty Ltd (Robert Peters) | 386,404,127 | 37.01 |
| 2 | Clermont Capital (Singapore) / Orchid Capital Investments | 156,174,826 | 14.96 |
| 3 | Ibsen Pty Ltd | 43,798,627 | 4.20 |
| 4 | Harech Pty Ltd | 16,773,550 | 1.61 |
| 5 | Not identified in source | 12,787,185 | 1.23 |
| 6 | Not identified in source | 11,148,234 | 1.07 |
| 7 | Dr Camile Farah | 9,135,279 | 0.87 |
| 8 | Not identified in source | 8,532,445 | 0.82 |
| 9 | Not identified in source | 5,123,823 | 0.49 |
| 10 | Not identified in source | 4,238,345 | 0.41 |
Competitive Landscape
Key Competitors
| Competitor | Listing | Technology / product | Overlap with Optiscan | Latest revenue (as available) |
|---|---|---|---|---|
Mauna Kea Technologies | Euronext Growth: ALMKT (France) | Cellvizio probe- and needle-based confocal laser endomicroscopy (p/nCLE) | Most direct confocal endomicroscopy competitor (GI, pancreatic cysts, urology) | FY2025 total sales €8.2M (+7%); completed court-supervised safeguard procedure and 70% debt reduction (FY2025 results, 22 Apr 2026) |
Perimeter Medical Imaging AI | TSXV: PINK / OTCQX: PYNKF (Canada/US) | Wide-field OCT with AI for breast surgery margins (S-Series; Claire/B-Series with FDA PMA approval in 2026) | Direct competitor to InVue in breast-conserving surgery margin assessment | FY2025 revenue ~US$2.3M (+172%); net loss ~US$12.9M (preliminary unaudited, 31 Mar 2026) |
Carl Zeiss Meditec | XETRA: AFX (Germany) | CONVIVO (uses Optiscan engine); broad surgical visualisation | Partner/customer; also controls the neurosurgery application | — |
SamanTree Medical | Private (Switzerland) | Histolog Scanner — ex vivo confocal imaging of fresh specimens | Direct competitor to InForm | — |
Lumicell | Private (US) | LUMISIGHT fluorescence-guided intraoperative margin imaging for breast cancer | Competes with InVue for breast margins | — |
Invenio Imaging | Private (US) | NIO stimulated Raman histology for rapid intraoperative pathology | Competes with InForm (neurosurgery, head & neck) | — |
MAVIG (VivaScope) | Private (Germany) | Reflectance/fluorescence confocal microscopes for ex vivo and dermatology | Competes in ex vivo confocal pathology | — |
OncoNano Medicine | Private (US) | pH-activated fluorescent imaging agent for intraoperative tumour visualisation | Alternative intraoperative tumour detection | — |
Leica Biosystems / Philips digital pathology | Danaher (NYSE: DHR) / Philips (AEX: PHIA) | Whole-slide imaging scanners and digital pathology software | Incumbent digital pathology workflows (post-processing rather than fresh tissue) | — |
Evident (formerly Olympus Scientific) and other microscope OEMs | Private (Bain Capital-owned) / various | Research and clinical microscopy | Research market overlap (ViewnVivo) | — |
Intuitive Surgical | NASDAQ: ISRG | da Vinci robotics with Firefly fluorescence imaging | Potential partner/competitor for robotic intraoperative imaging | — |
Conventional frozen section analysis | — | Standard of care for intraoperative pathology | Primary incumbent workflow both InVue and InForm aim to displace | — |
“—” = not publicly disclosed.
Peer Comparison FY2026
| Metric | Optiscan (FY2026, A$) | Mauna Kea Technologies (FY2025, €) | Perimeter Medical (FY2025, US$) |
|---|---|---|---|
Revenue | A$0.45M | €8.2M sales | ~US$2.3M |
Revenue growth | -52.9% | +7% | +172% |
Net result | -A$6.99M | — | ~-US$12.9M |
Net margin | -1,557% | — | ~-561% |
R&D intensity (R&D/revenue) | ~1,400% | — | — |
Regulatory status | 2 x 510(k) pending; vet product launched | FDA/CE cleared Cellvizio; CE MDR certified | FDA PMA approval of AI-enabled OCT device (2026) |



